Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: FUT8

Gene summary for FUT8

Gene summary.

Gene information	Species	Human
	Gene symbol	FUT8
	Gene ID	2530
	Gene name	fucosyltransferase 8
	Gene Alias	CDGF
	Cytomap	14q23.3
	Gene Type	protein-coding
	GO ID	GO:0001701
	UniProtAcc	Q546E0

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2530	FUT8	HTA11_1391_2000001011	Human	Colorectum	AD	2.11e-04	6.45e-01	-0.059
2530	FUT8	HTA11_99999965104_69814	Human	Colorectum	MSS	1.08e-02	4.53e-01	0.281
2530	FUT8	HTA11_99999971662_82457	Human	Colorectum	MSS	1.23e-05	-4.09e-01	0.3859
2530	FUT8	F007	Human	Colorectum	FAP	6.22e-04	3.95e-01	0.1176
2530	FUT8	A002-C-010	Human	Colorectum	FAP	3.91e-33	7.63e-01	0.242
2530	FUT8	A001-C-207	Human	Colorectum	FAP	1.80e-02	2.35e-01	0.1278
2530	FUT8	A015-C-203	Human	Colorectum	FAP	1.66e-16	-3.11e-01	-0.1294
2530	FUT8	A002-C-201	Human	Colorectum	FAP	1.07e-14	3.58e-01	0.0324
2530	FUT8	A002-C-203	Human	Colorectum	FAP	1.74e-20	6.75e-01	0.2786
2530	FUT8	A001-C-108	Human	Colorectum	FAP	1.07e-05	2.14e-01	-0.0272
2530	FUT8	A002-C-205	Human	Colorectum	FAP	4.65e-15	5.34e-02	-0.1236
2530	FUT8	A015-C-006	Human	Colorectum	FAP	9.12e-10	9.17e-03	-0.0994
2530	FUT8	A015-C-106	Human	Colorectum	FAP	1.01e-04	-1.10e-01	-0.0511
2530	FUT8	A002-C-114	Human	Colorectum	FAP	1.10e-10	-9.29e-02	-0.1561
2530	FUT8	A015-C-104	Human	Colorectum	FAP	3.28e-17	-4.13e-01	-0.1899
2530	FUT8	A001-C-014	Human	Colorectum	FAP	2.58e-05	1.59e-01	0.0135
2530	FUT8	A002-C-016	Human	Colorectum	FAP	1.93e-16	3.07e-01	0.0521
2530	FUT8	A015-C-002	Human	Colorectum	FAP	1.19e-05	-1.81e-01	-0.0763
2530	FUT8	A001-C-203	Human	Colorectum	FAP	8.53e-04	7.56e-02	-0.0481
2530	FUT8	A002-C-116	Human	Colorectum	FAP	5.61e-21	1.03e-01	-0.0452

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00442824	Stomach	GC	small molecule catabolic process	40/1159	376/18723	5.92e-04	8.09e-03	40
GO:19028826	Stomach	GC	regulation of response to oxidative stress	15/1159	98/18723	9.86e-04	1.18e-02	15
GO:000697911	Stomach	CAG with IM	response to oxidative stress	59/1050	446/18723	7.12e-10	1.02e-07	59
GO:001603211	Stomach	CAG with IM	viral process	55/1050	415/18723	2.54e-09	2.88e-07	55
GO:006219711	Stomach	CAG with IM	cellular response to chemical stress	43/1050	337/18723	4.05e-07	2.34e-05	43
GO:003459911	Stomach	CAG with IM	cellular response to oxidative stress	37/1050	288/18723	2.19e-06	9.55e-05	37
GO:190040711	Stomach	CAG with IM	regulation of cellular response to oxidative stress	15/1050	89/18723	1.19e-04	2.53e-03	15
GO:190288211	Stomach	CAG with IM	regulation of response to oxidative stress	15/1050	98/18723	3.54e-04	5.76e-03	15
GO:001605211	Stomach	CAG with IM	carbohydrate catabolic process	19/1050	154/18723	1.02e-03	1.29e-02	19
GO:000599611	Stomach	CAG with IM	monosaccharide metabolic process	26/1050	257/18723	2.67e-03	2.58e-02	26
GO:001931811	Stomach	CAG with IM	hexose metabolic process	24/1050	237/18723	3.77e-03	3.31e-02	24
GO:000697921	Stomach	CSG	response to oxidative stress	58/1034	446/18723	1.08e-09	1.46e-07	58
GO:001603221	Stomach	CSG	viral process	53/1034	415/18723	1.07e-08	9.41e-07	53
GO:006219721	Stomach	CSG	cellular response to chemical stress	42/1034	337/18723	6.94e-07	3.75e-05	42
GO:003459921	Stomach	CSG	cellular response to oxidative stress	36/1034	288/18723	3.99e-06	1.63e-04	36
GO:190040721	Stomach	CSG	regulation of cellular response to oxidative stress	15/1034	89/18723	9.99e-05	2.22e-03	15
GO:190288221	Stomach	CSG	regulation of response to oxidative stress	15/1034	98/18723	3.01e-04	5.17e-03	15
GO:001605221	Stomach	CSG	carbohydrate catabolic process	17/1034	154/18723	5.03e-03	4.12e-02	17
GO:0016032113	Thyroid	PTC	viral process	236/5968	415/18723	2.48e-26	8.24e-24	236
GO:0006979113	Thyroid	PTC	response to oxidative stress	234/5968	446/18723	6.97e-20	9.77e-18	234

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa00510	Colorectum	AD	N-Glycan biosynthesis	21/2092	53/8465	1.15e-02	4.24e-02	2.71e-02	21
hsa005101	Colorectum	AD	N-Glycan biosynthesis	21/2092	53/8465	1.15e-02	4.24e-02	2.71e-02	21
hsa005102	Colorectum	MSS	N-Glycan biosynthesis	20/1875	53/8465	7.17e-03	2.83e-02	1.73e-02	20
hsa00513	Colorectum	MSS	Various types of N-glycan biosynthesis	16/1875	42/8465	1.39e-02	4.53e-02	2.77e-02	16
hsa005103	Colorectum	MSS	N-Glycan biosynthesis	20/1875	53/8465	7.17e-03	2.83e-02	1.73e-02	20
hsa005131	Colorectum	MSS	Various types of N-glycan biosynthesis	16/1875	42/8465	1.39e-02	4.53e-02	2.77e-02	16
hsa05202	Colorectum	FAP	Transcriptional misregulation in cancer	45/1404	193/8465	9.19e-03	3.33e-02	2.03e-02	45
hsa052021	Colorectum	FAP	Transcriptional misregulation in cancer	45/1404	193/8465	9.19e-03	3.33e-02	2.03e-02	45
hsa0051023	Esophagus	ESCC	N-Glycan biosynthesis	39/4205	53/8465	3.26e-04	1.15e-03	5.89e-04	39
hsa005136	Esophagus	ESCC	Various types of N-glycan biosynthesis	31/4205	42/8465	1.23e-03	3.78e-03	1.93e-03	31
hsa052028	Esophagus	ESCC	Transcriptional misregulation in cancer	116/4205	193/8465	2.08e-03	5.95e-03	3.05e-03	116
hsa0051033	Esophagus	ESCC	N-Glycan biosynthesis	39/4205	53/8465	3.26e-04	1.15e-03	5.89e-04	39
hsa0051313	Esophagus	ESCC	Various types of N-glycan biosynthesis	31/4205	42/8465	1.23e-03	3.78e-03	1.93e-03	31
hsa0520213	Esophagus	ESCC	Transcriptional misregulation in cancer	116/4205	193/8465	2.08e-03	5.95e-03	3.05e-03	116
hsa052026	Lung	IAC	Transcriptional misregulation in cancer	40/1053	193/8465	6.90e-04	5.90e-03	3.92e-03	40
hsa0520211	Lung	IAC	Transcriptional misregulation in cancer	40/1053	193/8465	6.90e-04	5.90e-03	3.92e-03	40
hsa052022	Lung	AIS	Transcriptional misregulation in cancer	39/961	193/8465	2.15e-04	2.41e-03	1.54e-03	39
hsa052023	Lung	AIS	Transcriptional misregulation in cancer	39/961	193/8465	2.15e-04	2.41e-03	1.54e-03	39
hsa052024	Lung	MIAC	Transcriptional misregulation in cancer	22/507	193/8465	2.64e-03	2.26e-02	1.64e-02	22
hsa052025	Lung	MIAC	Transcriptional misregulation in cancer	22/507	193/8465	2.64e-03	2.26e-02	1.64e-02	22

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

FUT8

SNV

Missense_Mutation

c.109N>A

p.Asp37Asn

p.D37N

Q9BYC5

protein_coding

tolerated(0.08)

benign(0.12)

TCGA-A2-A0YK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

FUT8

SNV

Missense_Mutation

novel

c.601N>A

p.Pro201Thr

p.P201T

Q9BYC5

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FUT8

SNV

Missense_Mutation

novel

c.824N>C

p.Gly275Ala

p.G275A

Q9BYC5

protein_coding

tolerated(1)

benign(0.271)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

FUT8

insertion

Nonsense_Mutation

novel

c.1184_1185insATTCTAAGTGTTAGACGTAAAGAAGGTACATGTGAAGT

p.Arg396PhefsTer2

p.R396Ffs*2

Q9BYC5

protein_coding

TCGA-A2-A0EM-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

FUT8

SNV

Missense_Mutation

novel

c.643N>G

p.Asn215Asp

p.N215D

Q9BYC5

protein_coding

deleterious(0.01)

possibly_damaging(0.812)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FUT8

SNV

Missense_Mutation

novel

c.1097N>A

p.Arg366His

p.R366H

Q9BYC5

protein_coding

deleterious(0)

probably_damaging(0.994)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FUT8

SNV

Missense_Mutation

novel

c.1673N>C

p.Val558Ala

p.V558A

Q9BYC5

protein_coding

tolerated(0.2)

probably_damaging(0.994)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FUT8

SNV

Missense_Mutation

c.1033N>C

p.Glu345Gln

p.E345Q

Q9BYC5

protein_coding

tolerated(0.32)

benign(0.307)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FUT8

SNV

Missense_Mutation

rs765246656

c.1720G>A

p.Glu574Lys

p.E574K

Q9BYC5

protein_coding

tolerated(0.43)

benign(0.027)

TCGA-VS-A958-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

FUT8

insertion

Frame_Shift_Ins

novel

c.1200_1201insA

p.Arg403LysfsTer8

p.R403Kfs*8

Q9BYC5

protein_coding

TCGA-IR-A3LC-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unspecific

Cisplatin

Complete Response

Page: 1 2 3 4 5 6 7 8

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1